BioCentury | May 28, 2019
Distillery Therapeutics

LTB4 as a therapy for influenza A infection

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Mouse studies suggest LTB4 could help treat influenza A viral infection. In influenza A-infected mice, LTB4 decreased proliferation of inflammatory monocyte-derived macrophages in the lungs and increased survival...
BioCentury | Apr 26, 2019
Clinical News

Akari's Nomacopan reduces skin inflammation in Phase II

Akari said initial data from three patients with bullous pemphigoid in a Phase II trial showed Nomacopan (Coversin) reduced symptoms of the orphan skin disease. Akari Therapeutics plc (NASDAQ:AKTX) said Nomacopan reduced BP Disease Area...
BioCentury | Sep 10, 2018
Distillery Therapeutics


...CONTACT: Jonathan Bromberg, University of Maryland School of Medicine, Baltimore, Md. email: Chris Lieu University of Maryland Lymphotoxin beta...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
BioCentury | Mar 9, 2018
Clinical News

Phase I/II of Roche PNH candidate temporarily halted

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said enrollment was temporarily stopped in the Phase I/II COMPOSER trial evaluating RG6107 (SKY59) in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) after two patients who received RG6107...
BioCentury | Feb 23, 2018
Clinical News

Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial...
BioCentury | Jan 19, 2018
Clinical News

Eiger discontinues ubenimex for PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) discontinued development of ubenimex to treat pulmonary arterial hypertension (PAH). The company made the decision after the product missed the primary endpoint in the Phase II LIBERTY trial in the indication....
BioCentury | Jan 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Sepsis; fungal infection Mouse studies suggest inhibiting BLT1 could help treat fungal sepsis. In a mouse model of Candida albicans -induced fungal sepsis, systemic knockout of BLT1 decreased hemorrhage and capillaritis in the lung...
BioCentury | Jan 16, 2018
Clinical News

Phase II PAH readout sinks Eiger shares

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) lost $7.90 (49%) to $8.10 Tuesday after discontinuing development of ubenimex to treat pulmonary arterial hypertension. The company made the decision after the product missed the primary endpoint in the Phase...
BioCentury | Sep 21, 2017
Clinical News

Akari gains on Phase III PNH plans for C5 inhibitor

Akari Therapeutics plc (NASDAQ:AKTX) gained $3.15 (56%) to $8.74 on Thursday after the company announced plans to start Phase III testing in 1Q18 of lead candidate Coversin to treat paroxysmal nocturnal hemoglobinuria. The announcement appears...
Items per page:
1 - 10 of 87